BOUNDLESS BIO INC (BOLD) Stock Price, Quote, News and Overview
NASDAQ:BOLD - Nasdaq - US10170A1007 - Common Stock - Currency: USD
BOLD Quote, Performance and Key Statistics
NASDAQ:BOLD (7/18/2025, 8:00:01 PM)
1.21
+0.03 (+2.54%)
The current stock price of BOLD is 1.21 USD. In the past month the price increased by 16.35%. In the past year, price decreased by -66.01%.
BOLD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.43 | 334.31B | ||
| AMGN | AMGEN INC | 14.2 | 158.50B | ||
| GILD | GILEAD SCIENCES INC | 13.98 | 134.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.24 | 58.58B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.79B | ||
| ARGX | ARGENX SE - ADR | 98.19 | 34.47B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.53 | 31.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.45B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.46B | ||
| INSM | INSMED INC | N/A | 19.46B | ||
| NTRA | NATERA INC | N/A | 18.97B |
Related stock screener links
About BOLD
Company Profile
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2024-03-28. Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
Company Info
BOUNDLESS BIO INC
10955 Alexandria Way, Suite 100
San Diego CALIFORNIA 94108 US
CEO: Matthew R. Patterson
Employees: 64
Phone: 18587669912
BOUNDLESS BIO INC / BOLD FAQ
What is the stock price of BOUNDLESS BIO INC today?
The current stock price of BOLD is 1.21 USD. The price increased by 2.54% in the last trading session.
What is the ticker symbol for BOUNDLESS BIO INC stock?
The exchange symbol of BOUNDLESS BIO INC is BOLD and it is listed on the Nasdaq exchange.
On which exchange is BOLD stock listed?
BOLD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BOUNDLESS BIO INC stock?
9 analysts have analysed BOLD and the average price target is 4.08 USD. This implies a price increase of 237.19% is expected in the next year compared to the current price of 1.21. Check the BOUNDLESS BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BOUNDLESS BIO INC worth?
BOUNDLESS BIO INC (BOLD) has a market capitalization of 27.09M USD. This makes BOLD a Nano Cap stock.
How many employees does BOUNDLESS BIO INC have?
BOUNDLESS BIO INC (BOLD) currently has 64 employees.
What are the support and resistance levels for BOUNDLESS BIO INC (BOLD) stock?
BOUNDLESS BIO INC (BOLD) has a support level at 1.12 and a resistance level at 1.22. Check the full technical report for a detailed analysis of BOLD support and resistance levels.
Should I buy BOUNDLESS BIO INC (BOLD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BOLD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BOLD, evaluating the profitability, health, valuation and growth aspects
- BOUNDLESS BIO INC (BOLD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BOUNDLESS BIO INC (BOLD) Sales and EPS estimates to see what analysts future expectations are.
- BOUNDLESS BIO INC (BOLD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BOUNDLESS BIO INC (BOLD) Insider and Institutional Ownership to learn about the owners and their transactions.
- BOUNDLESS BIO INC (BOLD) Stock Chart to make your own analysis
- BOUNDLESS BIO INC (BOLD) Latest news and press-releases to stay up to date.
Does BOUNDLESS BIO INC (BOLD) stock pay dividends?
BOLD does not pay a dividend.
What is the Price/Earnings (PE) ratio of BOUNDLESS BIO INC (BOLD)?
BOUNDLESS BIO INC (BOLD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.96).
What is the Short Interest ratio of BOUNDLESS BIO INC (BOLD) stock?
The outstanding short interest for BOUNDLESS BIO INC (BOLD) is 0.68% of its float. Check the ownership tab for more information on the BOLD short interest.
BOLD Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BOLD. When comparing the yearly performance of all stocks, BOLD is a bad performer in the overall market: 96.13% of all stocks are doing better.
BOLD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BOLD. While BOLD has a great health rating, there are worries on its profitability.
BOLD Financial Highlights
Over the last trailing twelve months BOLD reported a non-GAAP Earnings per Share(EPS) of -2.96. The EPS decreased by -456.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.35% | ||
| ROE | -48.09% | ||
| Debt/Equity | 0 |
BOLD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to BOLD. The Buy consensus is the average rating of analysts ratings from 9 analysts.